Guillermo Montalban Bravo, M.D.
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2022 | Educational Commission for Foreign Medical Graduates, Madrid, ESP, ECFMG Certification, Steps 1,2 CK , 2 CS and 3 |
| 2014 | CNIO Spanish National Center on Investigational Oncology, Madrid, ESP, MS, Molecular Oncology |
| 2010 | Autonomous University of Madrid, Madrid, ESP, MD, Medical Doctor |
| 2004 | King's College Madrid, Madrid, ESP, BS, Pre-Medical |
Postgraduate Training
| 2015-2017 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2015-2015 | Certification, ECGMG Certification USMLE, Educational Commission for Foreign Medical Graduates, Philadelpha, PA |
| 2013-2013 | Observership, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2013-2013 | Elective Rotation, Molecular Cytogenetics, CNIO Spanish National Center on Investigational Oncology, Madrid |
| 2011-2015 | Specialist, Hematology and Hemotherapy, Spanish Ministry of Healthcare, Social Services and Equality - University Hospital La Paz, Madrid |
| 2011-2015 | Clinical Fellowship, Hematology and Hemotherapy, University Hospital La Paz, Madrid |
Board Certifications
| 2015 | Spanish Society of Hematology and Hemotherapy |
Honors & Awards
| 2016 - 2017 | Best Research Fellow, The University of Texas MD Anderson Cancer Center Department of Leukemia |
| 2015 - 2016 | Fellow of The Year, The University of Texas MD Anderson Cancer Center Department of Leukemia |
| 2008 - 2009 | Grant for Exceptional Academical Achievements, Education Council of Madrid, Spain |
| 2007 - 2008 | Grant for Exceptional Academical Achievements, Education Council of Madrid, Spain |
| 2006 - 2007 | Grant for Exceptional Academical Achievements, Education Council of Madrid, Spain |
Selected Publications
Peer-Reviewed Articles
- Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. e-Pub 2023. PMID: 37946611.
- Montalban-Bravo G , Takahashi K, Garcia-Manero G. Decitabine in TP53-Mutated AML. N Engl J Med 376(8):796-7, 2017. PMID: 28229579.
Other Articles
- Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez IG, Rodriguez-Sevilla JJ, Adema V, Wildeman B, Lockyer P, Kim YJ, Tanaka T, Darbaniyan F, Pancholy S, Zhang G, Al-Atrash G, Dwyer K, Takahashi K, Garcia-Manero G, Kantarjian H, Colla S Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia. bioRxiv, 2023. PMID: 37066354.
Abstracts
- Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alavarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JC, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130(Suppl 1):2967, 2017.
- Alfonso Pierola A, Assi R, KC D, Abaza Y, Abou Zahr A, Chamoun K, Montalban Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel KP, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia. Blood 130(Suppl 1 3852), 2017.
- Naqvi K, Montalban Bravo G, Alfonso Pierola A, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Kadia T, Pierce S, Borthakur G, Daver N, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, Gonzalez GN, Kantarjian HM, Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 130(Suppl 1 4258), 2017.
- Jabbour EJ, Short NJ, Montalban Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes JE, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian HM, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood 130(No. 13):1514-1522, 2017.
- Montalban Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian HM, Young KH, Garcia-Manero G, and Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(No. 18):2584-2587, 2017. e-Pub 2017.
- Ana Alfonso Pierola, Guillermo Montalban-Bravo, Koichi Takahashi, Elias Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney Denton Dinardo, Naval Guastad Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Carlos E. Bueso-Ramos, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero. Impact of the type of first-cancer therapy in therapy-related myelodysplastic syndromes outcomes. J Clin Oncol suppl(35), 2017.
- Guillermo Montalban-Bravo, Ana Alfonso Pierola, Koichi Takahashi, Marina Konopleva, Elias Jabbour, Gautam Borthakur, Naval Guastad Daver, Courtney Denton Dinardo, Zeev Estrov, Tapan M. Kadia, Naveen Pemmaraju, Farhad Ravandi, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Keyur Patel, Guillermo Garcia-Manero. Clinical relevance of mutations in patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms with normal karyotype. J Clin Oncol suppl(35), 2017.
- Guillermo Montalban-Bravo, Prithviraj Bose, Yesid Alvarado, Naval Guastad Daver, Farhad Ravandi, Gautam Borthakur, Koichi Takahashi, Michael Andreeff, Jorge E. Cortes, Courtney Denton Dinardo, Elias Jabbour, Tapan M. Kadia, Steven Kornblau, Maro Ohanian, Xuelin Huang, Graciela M. Nogueras-Gonzalez, Kristy Bodden, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero. Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia. J Clin Oncol suppl(35), 2017.
- Rita Elias Assi, Ana Alfonso Pierola, Devendra KC, Yasmin Mohammed Abaza, Abdallah Abou Zahr, Kamal Chamoun, Guillermo Montalban-Bravo, Koichi Takahashi, Elias Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney Denton Dinardo, Naval Guastad Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Andrew Futreal, Hagop M. Kantarjian, Guillermo Garcia-Manero, Sherry Pierce. Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML). J Clin Oncol suppl(35), 2017.
- Ganan-Gomez I, Alfonso A, Ogoti Y, Yang H, Montalban Bravo G, Yu AC, Marchesini M, Bueso-Ramos C, Takahashi K, Clise-Dwyer K, Garcia-Manero G, and Colla S. Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes. Blood 128(No. 22):4310, 2016.
- Alfonso Pierola A, Marchesini M, Takahashi K, Ganan-Gomez I, Fiorini E, Ogoti Y, Irles E, Montalban Bravo G, Sofia S, Dwyer KC, Garcia-Manero G, and Colla S. The Role of Chip-Related DNA Damage Response Dysfunction in Therapy-Related Myeloid Neoplasms. Blood 128(No. 22):958, 2016.
Letters to the Editor
- Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol, 2021.
- Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Leukemia 35: 1494-1499, 2021.
- Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in Oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol, 2020.
- Montalban-Bravo G, Takahashi K, Garcia-Manero G. Decitabine in TP53-Mutated AML. Engl J Med: 796-798, 2017.
- Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129: 2584-2587, 2017.
Grant & Contract Support
| Date: | 2023 - 2024 |
| Title: | Evaluating the role of STING activation in MDS and CMML |
| Funding Source: | Takeda Global Research and Development |
| Role: | Principal Investigator |
| Date: | 2022 - 2027 |
| Title: | Specialized Center of Research: An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-Program Leader |
| Date: | 2020 - 2021 |
| Title: | Identifying Mechanisms of Progression and Failure to Hypomethylating agents in Oligomonocytic Chronic Myelomonocytic Leukemia (CMML) and CMML, National Cancer Institute |
| Funding Source: | National Cancer Institute |
| Role: | Principal Investigator |
| Date: | 2019 - 2025 |
| Title: | 2019-0339: Phase 2, Open-Label, Study of Subcutaneous canakinumab, an Anti-IL-1B Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia |
| Funding Source: | Novartis |
| Role: | Co-Investigator |
| Title: | 2023-0110: Phase I/II Study of SY-1425 (Tamibarotene) in Combination with Azacitidine and Venetoclax for patients with Higher risk Chronic Myelomonocytic Leukemia |
| Funding Source: | Syros Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | |
| Funding Source: | IdiPAZ, University Hospital La Paz (Madrid, SPAIN) |
| Role: | Co-Investigator |
| ID: | Evaluating Endothelial and Hepatocellular Damage and Liver Fibrosis in Sinusoidal Obstructive Syndrome: Usefulness of Biomarkers and Transition Elastography |
Patient Reviews
CV information above last modified May 22, 2024